Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05449340
Other study ID # Prix Ruban Rose/2020/FF-03
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 25, 2022
Est. completion date February 16, 2024

Study information

Verified date February 2024
Source Centre Hospitalier Universitaire de Nimes
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project is a follow-on study of the BEAUTIFY-2 study (NCT04957186). The "BEAUTIFY" (BrEast cAncer qUaliTy of lIfe aFter surgerY) program was built by a committee of experts on the basis of reflections carried out within 2 focus groups. An application was developed to track patient reported outcome measures. The study investigators now wish to evaluate the feasibility and impact on pain and quality of life of the "BEAUTIFY" care pathway on a larger cohort. The study hypothesis is that multidisciplinary care organization will improve the management and the quality of life post-breast cancer surgery.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date February 16, 2024
Est. primary completion date February 16, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Breast cancer patient scheduled for surgery - Patient able to use a connected electronic object and having a tablet or a smartphone with internet access at home. - The patient must have given their free and informed consent and signed the consent form - The patient must be a member or beneficiary of a health insurance plan Exclusion Criteria: - The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study - The subject unable to express consent - It is impossible to give the subject informed information - The patient is under safeguard of justice or state guardianship

Study Design


Related Conditions & MeSH terms


Intervention

Device:
BEAUTIFY application
Interview with the coordinating nurse in the postoperative period to install the BEAUTIFY application on the patient's smartphone and to train her to record any Patients will monitor their symptoms weekly. In case of toxicity grade > 2, the nurse will contact the patient for further information.

Locations

Country Name City State
France CHU de Nîmes Nîmes

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient compliance with the program Yes/No: study will be considered feasible if at least 80% of patients complete the program End of study (12 months)
Primary Patient satisfaction with the intervention Yes/No: study will be considered feasible if at least 80% of patients are satisfied. End of study (12 months)
Secondary Compliance with completing the BEAUTIFY application % of weeks where information is recorded out of the total number of weeks End of study (12 months)
Secondary Patient quality of life following surgery European Organisation For Research And Treatment Of Cancer Quality of Life of Cancer Patients (EORTC QLQ C30): score of 1-7 for each item Baseline
Secondary Patient quality of life following surgery EORTC QLQ C30: score of 1-7 for each item 1 month
Secondary Patient quality of life following surgery EORTC QLQ C30: score of 1-7 for each item 3 months
Secondary Patient quality of life following surgery EORTC QLQ C30: score of 1-7 for each item 6 months
Secondary Satisfaction of patients with their care EORTC PATSAT-C33: score 0-100 1 month
Secondary Satisfaction of patients with their care EORTC PATSAT-C33: score 0-100 3 months
Secondary Satisfaction of patients with their care EORTC PATSAT-C33: score 0-100 6 months
Secondary Rate of post-operative complications % patients with a complication noted in medical file 6 months
Secondary Type of post-operative complications List of the complications affected patients as noted in medical file 6 months
Secondary Readmission rate for surgical or medical reason % patients readmitted 6 months
Secondary Return to work and/or social activities Date: Patients contacted by email or telephone 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A